Data gathered: October 27
Alternative Data for BioNTech
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 137 | Sign up | Sign up | Sign up |
| Sentiment | 56 | Sign up | Sign up | Sign up |
| Webpage traffic | 116,000 | Sign up | Sign up | Sign up |
| Employee Rating | 62 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 34 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 18,984 | Sign up | Sign up | Sign up |
| Twitter Followers | 80,646 | Sign up | Sign up | Sign up |
| Twitter Mentions | 28 | Sign up | Sign up | Sign up |
| X Mentions | 1 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 33 | Sign up | Sign up | Sign up |
| Linkedin Employees | 5,010 | Sign up | Sign up | Sign up |
About BioNTech
BioNTech SE is a German biotechnology company based in Mainz that develops and manufactures active immunotherapies for patient-specific approaches to the treatment of diseases.
| Price | $106.05 |
| Target Price | Sign up |
| Volume | 340,960 |
| Market Cap | $25.4B |
| Year Range | $86.65 - $122.75 |
| Dividend Yield | 0% |
| PE Ratio | 160.8 |
| Analyst Rating | 81% buy |
| Earnings Date | November 3 '25 |
| Industry | Biotechnology |
In the news
BioNTech to Report Third Quarter 2025 Financial Results and Corporate Update on November 3, 2025October 27 - GlobeNewswire |
|
 |
BioNTech price target lowered by $4 at BofA, here's whyOctober 22 - Thefly.com |
 |
BioNTech commences public exchange offer for CureVac sharesOctober 22 - Thefly.com |
BioNTech Commences Public Exchange Offer for All Outstanding Shares of CureVac N.V.October 22 - GlobeNewswire |
|
Moderna Vs BioNTech: Who's Winning The Post-COVID RaceOctober 17 - SeekingAlpha |
|
 |
BioNTech secures $110 million for Rwanda vaccine plantOctober 15 - Biztoc.com |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q2 '25 | 261M | 76M | 184M | -387M | -348M | -1.600 |
| Q1 '25 | 183M | 84M | 99M | -416M | -369M | -1.821 |
| Q4 '24 | 1.19B | 244M | 947M | 260M | 278M | 1.080 |
| Q3 '24 | 1.24B | 177M | 1.07B | 195M | 211M | 0.880 |
| Q2 '24 | 129M | 60M | 69M | -812M | -752M | -3.360 |
Insider Transactions View All
No recorded Insider transactions.
Similar companies
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Joshua Gottheimer Democrat |
May 15, 24 | Buy | $1K - $15K |
| Joshua Gottheimer Democrat |
Apr 7, 24 | Sell | $1K - $15K |
| Joshua Gottheimer Democrat |
Jan 7, 24 | Buy | $1K - $15K |
Read more about BioNTech (BNTX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of BioNTech?
The Market Cap of BioNTech is $25.4B.
What is BioNTech's PE Ratio?
As of today, BioNTech's PE (Price to Earnings) ratio is 160.8.
When does BioNTech report earnings?
BioNTech will report its next earnings on November 3 '25.
What is the current stock price of BioNTech?
Currently, the price of one share of BioNTech stock is $106.05.
How can I analyze the BNTX stock price chart for investment decisions?
The BNTX stock price chart above provides a comprehensive visual representation of BioNTech's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling BioNTech shares. Our platform offers an up-to-date BNTX stock price chart, along with technical data analysis and alternative data insights.
Does BNTX offer dividends to its shareholders?
As of our latest update, BioNTech (BNTX) does not offer dividends to its shareholders. Investors interested in BioNTech should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of BioNTech?
Some of the similar stocks of BioNTech are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.
